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Guoming Huang,a Juan Hu,a Hui Zhang,a Zijian Zhou,a Xiaoqin Chib and Jinhao Gao*aThis paper reports that iron carbide nanoparticles with high air-
stability and strong saturation magnetization can serve as effective T2
contrast agents for magnetic resonance imaging. Fe5C2 nanoparticles
(20 nm in diameter) exhibit strong contrast enhancement with an r2
value of 283.2 mM1 S1, which is about twice as high as that of
spherical Fe3O4 nanoparticles (140.9 mM1 S1). In vivo experiments
demonstrate that Fe5C2 nanoparticles are able to producemuchmore
significant MRI contrast enhancement than conventional Fe3O4
nanoparticles in living subjects, which holds great promise in
biomedical applications.Magnetic resonance imaging (MRI), based on the interaction of
protons with the surrounding molecules of tissues that can
provide excellent anatomical details, is currently one of the most
powerful medical imaging techniques.1 MRI contrast agents are a
group of contrast media that can greatly improve the accuracy
and specicity of MRI by enhancing the visibility of the target
from the background.2–5 For example, superparamagnetic iron
oxide nanoparticles with the ability to shorten T2 relaxation times
are one of the most common negative contrast agents and have
been used in the clinic.6–8 However, iron oxide nanoparticles with
relatively low saturation magnetization exhibit moderate T2
contrast enhancement. The transverse relaxivity (r2) values of
commercial iron oxide based contrast agents, such as ferum-
oxides, ferumoxtran, and ferumoxsil, are typically in the range
50–110 mM1 S1 at 0.47 T.9 Recently, intensive research has
been devoted to synthesizing highly magnetic nanoparticles,
since nanoparticles with larger saturation magnetizations can
more effectively shorten T2 relaxation times, resulting in greaterof Solid Surfaces, The Key Laboratory for
partment of Chemical Biology, College of
en University, Xiamen 361005, China.
189959; Tel: +86-592-2180278
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9/c3nr04691eMRI contrast enhancement.10–12 For example, manganese or zinc-
doped iron oxide nanoparticles with high magnetization and
increased relaxivity have been developed.13–16 However, doping
nanoparticles with potentially toxic metals has always been a
concern because of their harmful effects in living organisms. Iron
has the highest saturationmagnetization at room temperature of
any element,17 and has been shown to be a safe element in the
body aer the biodegradation of iron oxide nanoparticles,18,19
suggesting that iron nanoparticles may be ideal contrast agents
for high-performance MRI. Despite tremendous efforts, the
development of stable iron nanoparticles remains challenging
due to the fast oxidation of iron and the signicant loss of
magnetization upon exposure to air,20 which hampers the further
biomedical applications. Therefore, it is necessary to develop a
suitable iron-based contrast agent that not only has a large
saturation magnetization value, but also is stable in biological
media for diagnostic applications.
Iron carbides have attracted considerable attention over the
past several decades owing to their distinguished properties
and promising applications. Recently, several studies have been
focused on the synthesis of iron carbide nanostructures with
controlled size and morphology.21–24 Iron carbide nanoparticles
exhibit excellent catalytic activity and high magnetization, and
hold great promise for applications in catalysis and magnetic
hyperthermia.23,24 Herein, we investigate the stability of iron
carbide nanoparticles with high saturation magnetization and
report that Fe5C2 nanoparticles can serve as biocompatible and
effective T2 contrast agents for in vivo MRI.
The transmission electron microscopy (TEM) image shows
that the as-synthesized Fe5C2 nanoparticles were 20 nm in
diameter with spherical and rod-shaped structures (Fig. 1a).
The high-resolution TEM (HRTEM) image reveals that the
lattice spacing in the core was 0.205 nm, corresponding to the
(510) plane of Fe5C2, while the shell was amorphous (Fig. 1b).
The X-ray powder diffraction (XRD) pattern conrms that the
crystal structure of iron carbide nanoparticles is consistent with
that of Fe5C2 (JCPDS no. 36-1248). We further employed X-ray
photoelectron spectroscopy (XPS) to investigate the surfaceThis journal is © The Royal Society of Chemistry 2014
Fig. 1 (a) TEM image and size distribution histogram (inset), (b) HRTEM
image, (c) XRD pattern, and (d) Fe 2p XPS spectrum of Fe5C2 nanoparticles.
Fig. 2 (a) Magnetic hysteresis loop of the Fe5C2 nanoparticles recor-
ded at 300 K (inset: magnification of the low-field region). (b) Stability














































View Article Onlinenature of Fe5C2 nanoparticles (Fig. 1d). The peak at 707 eV in
the Fe 2p XPS spectrum can be ascribed to the Fe–C bond,23
indicating the successful synthesis of iron carbide nano-
particles. Two peaks at 710.4 eV and 724 eV can be assigned
to iron(III) oxide,25 together with the peak at 284 eV in the C 1s
spectrum (Fig. S1†), indicating the coexistence of the iron oxide
and the carbon amorphous shell.23
We then investigated the magnetic properties of Fe5C2
nanoparticles using a superconducting quantum interference
device (SQUID) magnetometer. The hysteresis loop shows that
the as-synthesized Fe5C2 nanoparticles exhibit a so ferro/
ferrimagnetic behavior with a saturation magnetization value of
120 emu g1 at 300 K (Fig. 2a). This saturation magnetization
value is very close to that of the iron carbides reported previ-
ously,22,26 and is much higher than that of iron oxide nano-
particles with similar size (typically range from 40–70 emu
g1).27–29 Remarkably, the Fe5C2 nanoparticles also display a
high stability against oxidation. The Fe5C2 nanoparticles show
little magnetization change even aer two month air exposure
(Fig. 2b). The highly crystalline structure and the presence of
carbon atoms may prevent the oxidation of Fe5C2 nanoparticles.
For comparison, we synthesized the amorphous Fe (denoted as
amor-Fe) nanoparticles20 with 14 nm in diameter and studied
the stability in air. The saturation magnetization of the freshly
prepared 10 nm Fe nanoparticles has been reported up to
198 emu g1.24 In our experiment, the saturation magnetization
of the as-synthesized14 nm amor-Fe nanoparticles dropped to
100 emu g1 only aer 1 day air exposure, and was further
decreased to 26 emu g1 aer 30 days. Obviously, the Fe5C2
nanoparticles are much more stable than amor-Fe nano-
particles in air, suggesting that Fe5C2 nanoparticles with great
feature of excellent oxidation resistance are suitable for further
potential applications.This journal is © The Royal Society of Chemistry 2014To make the as-synthesized Fe5C2 nanoparticles water-
dispersible for biomedical applications, we simply modied the
particle surface with sodium tartrate via a ligand exchange
method. The obtained aqueous solution containing Fe5C2
nanoparticles is highly stable over at least three months without
any precipitate (Fig. S2†), suggesting that tartrate-coated Fe5C2
nanoparticles are suitable for in vitro and in vivo studies. The
morphology of nanoparticles shows no obvious change as
observed in TEM images (Fig. S2†). The dynamic light scattering
(DLS) analysis indicates that the tartrate-coated Fe5C2 nano-
particles are very stable without aggregation in aqueous solu-
tion (Fig. S3†). We then evaluated the cytotoxicity of the water-
dispersible Fe5C2 nanoparticles using the tetrazolium-based
colorimetric assay (MTT assay). The result shows that more than
85% of cells were viable even at the highest concentration (100
mg Fe mL1,1.8 mM, measured by inductively coupled plasma
atomic emission spectroscopy, ICP-AES), indicating the good
biocompatibility of tartrate-coated Fe5C2 nanoparticles (Fig. 3).
We next investigated the ability of Fe5C2 nanoparticles for
MRI contrast enhancement. We used Fe3O4 nanoparticles
(20 nm in diameter) and amor-Fe nanoparticles (14 nm in
diameter) as two control samples (Fig. S4†). All tartrate-coated
solution samples have been stored in the air for one month. We
rst prepared samples of these three types of nanoparticles with
different Fe concentrations (determined by ICP-AES) and
collected the T2-weighted phantom images at a 0.5 T MRI
system. For a given Fe concentration, Fe5C2 nanoparticles
exhibit the strongest negative contrast effect (darken signal)
among three types of nanoparticles, suggesting the capability of
Fe5C2 nanoparticles as high-performance T2 MRI contrast
agents (Fig. 4a). We further measured the transverse relaxivity
(r2) at 0.5 T according to the linear relationship of transverseNanoscale, 2014, 6, 726–730 | 727
Fig. 3 Cell viability of HeLa cells after being incubated with Fe5C2














































View Article Onlinerelaxation rates (R2, i.e., 1/T2) versus Fe concentrations (Fig. 4b).
The r2 value of Fe5C2 nanoparticles is283.2 mM1 S1, which is
about twice as high as that of Fe3O4 nanoparticles (140.9 mM1
S1) and also much higher than those of commercial T2 contrastFig. 4 (a) T2-weighted phantom images of Fe5C2 nanoparticles, Fe3O4
nanoparticles, and amor-Fe nanoparticles in aqueous solution (con-
taining 1% agar) with different Fe concentrations, respectively. (b) The
linear fitting of relaxation rates (R2) versus Fe concentrations for Fe5C2
nanoparticles, Fe3O4 nanoparticles, and amor-Fe nanoparticles,
respectively. The relaxivity values (r2) were obtained from the slopes.
728 | Nanoscale, 2014, 6, 726–730agents (e.g., ferumoxides),9 conrming that Fe5C2 nanoparticles
have much stronger T2 contrast enhancement than Fe3O4 nano-
particles. On the basis of the quantum mechanical outer sphere
theory, the T2 relaxivity is highly dependent on the saturation
magnetization of the nanoparticles.12,30,31 Fe5C2 nanoparticles
with high saturation magnetization can afford effective magnetic
relaxations to the water protons around the nanoparticles and
therefore results in the enhanced relaxivity.32,33 The r2 value of
amor-Fe nanoparticles is only 12.7 mM1 S1, which is extremely
lower than those of Fe5C2 nanoparticles and Fe3O4 nanoparticles.
The signicant loss of magnetization results in the poor perfor-
mance of amor-Fe nanoparticles in MRI contrast enhancement.
Moreover, the further oxidation and instability of amor-Fe
nanoparticlesmake them unsuitable for biomedical applications.
Thus, we only used Fe5C2 nanoparticles and Fe3O4 nanoparticles
as samples in subsequent in vivo MRI experiments.
Iron oxide nanoparticles have been extensively developed for
the diagnosis of liver diseases because they are highly taken up
by the hepatic Kupffer cells.34–36 Thus, we focused on the liver as
the targeting region for evaluating the in vivo MRI effects of
Fe5C2 nanoparticles. The r2 values of the Fe5C2 and Fe3O4
nanoparticles are 428.5 and 232.2 mM1 S1 at 7 T, respectively
(Fig. S5†). Meanwhile, the r2 value of Fe5C2 nanoparticles is
approximately two times larger than that of Fe3O4 nano-
particles, which is consistent with the results obtained at 0.5 T.
We intravenously injected Fe5C2 nanoparticles and Fe3O4
nanoparticles into the BALB/c mice (dosage of 2.0 mg Fe per kg,
Fe concentration determined by ICP-AES) and obtained T2-
weighted images at different time points aer injection on a 7 T
Varian MRI scanner. Fe5C2 nanoparticles and Fe3O4 nano-
particles may have comparable biodistribution (e.g., similar
liver uptake of nanoparticles) because of their similar size and
surface chemistry.37,38 Both coronal and transverse images show
that the liver regions exhibited a noticeably darker signal aer
the injection of Fe3O4 and Fe5C2 nanoparticles (Fig. 5a and S6†).
In comparison with Fe3O4 nanoparticles, Fe5C2 nanoparticles
produced signicantly darker signal in liver regions probably
due to their higher r2 value. To quantify the contrast enhance-
ment, we calculated the signal-to-noise ratio (SNR) by nely
analyzing regions of interest (ROIs) of the transverse images
and dened the contrast enhancement as the decrease of SNR,
OSNR ¼ (|SNRpost  SNRpre|)/SNRpre. The measured OSNR
values of the Fe5C2 nanoparticle group are 54.1  7.3%, 68.8 
5.4%, 85.0  3.8%, 58.8  7.7% at 0.5, 1 h, 2 h, 4 h aer the
injection, respectively, which is much higher than those of the
Fe3O4 nanoparticle group (26.8  3.4%, 43.7  3.2%, 47.1 
1.7%, and 27.9 3.0%, respectively), further demonstrating the
excellent contrast ability of Fe5C2 nanoparticles in MRI of small
living subjects (Fig. 5b). It is worth noting that the OSNR
values have been falling at 4 h, and further decrease to 28.2 
5.4% and 15.3  2.2% 24 h aer the injection of Fe5C2 and
Fe3O4 nanoparticles, respectively. It is necessary to conduct
MRI scanning within 2–4 h aer administration of Fe5C2
nanoparticles, which also meets the basic requirements of
clinical diagnosis.
In summary, we successfully synthesized Fe5C2 nanoparticles
and investigated their ability to serve as high-performance T2This journal is © The Royal Society of Chemistry 2014
Fig. 5 (a) T2-weighted in vivo MRI images of mice (transverse plane)
collected at different time points after intravenous injection of Fe5C2
nanoparticles and Fe3O4 nanoparticles (with a dose of 2.0mg Fe per kg
of mouse body weight), respectively. (b) The decrease of signal-to-
noise ratio (OSNR) at different time points after intravenous injection














































View Article Onlinecontrast agents. The as-synthesized 20 nm Fe5C2 nanoparticles
have a high saturation magnetization (120 emu g1) and
remarkable oxidation resistance. Both in vitro and in vivo
studies demonstrated that the Fe5C2 nanoparticles were able to
effectively shorten T2 relaxation times (with an r2 value of
283.2 mM1 S1 at 0.5 T) and produce signicant MRI contrast
enhancement. We believe that such highly magnetic and stable
iron carbide nanoparticles hold great promise in serving as
novel and effective MRI contrast agents for liver imaging.
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